VALANX Biotech secures AWS Seed funding

AWS Seed funding round was successfully completed and secures financial stability of VALANX Biotech

AWS Seed funding for product development

In October we managed to obtain a significant grant from Austria Wirtschaftsservice. This will significantly propel our company forward and drive the development of our first showcase product based on our site-specific protein conjugation platform technology. This product will not only showcase the capabilities of our technology platform but will also provide significant improvements in the treatment of various autoimmune diseases.
Big thanks to the great team but also to the support from AWS during preparation for the pitch and to our investors SOSVIST cube, and tecnet equity for their continued support and backing.